Eisai and Nuvation Bio Secure EMA Validation for Taletrectinib in Lung Cancer
EU regulator begins review of next-generation targeted therapy for advanced ROS1-positive non-small cell lung cancer.
Targeted Therapy | 30/03/2026 | By News Bureau | 128
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy